1. FerlayJ, SoerjomataramI, ErvikM, et al.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr, accessed March 2014.

2. National Cancer Institute. Colon and rectal cancer. Available at: http://www.cancer.gov/cancertopics/types/colon-and-rectal, accessed June 2014.

3. JemalA, MurrayT, SamuelsA, et al.Cancer statistics, 2003. CA Cancer J Clin2003;53:5. CrossRef

4. SiegelR, NaishadhamD, JemalA. Cancer statistics, 2013. CA Cancer J Clin2013;63:11. CrossRef

5. RiesLAG, KosaryCL, HankeyBF, et al.SEER Cancer Statistics Review 1973–1995. Bethesda, MD: National Cancer Institute; 1998.

6. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: http://www.seer.cancer.gov, accessed June 2014.

7. SiegelR, NaishadhamD, JemalA. Cancer statistics, 2012. CA Cancer J Clin2012;62:10. CrossRef

8. FerlitschM, ReinhartK, PramhasS, et al.Sex‐specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA2011;306:1352. CrossRef

9. MurphyG, DevesaSS, CrossAJ, et al.Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer2011;128:1668. CrossRef

10. NishiharaR, WuK, LochheadP, et al.Long‐term colorectal‐cancer incidence and mortality after lower endoscopy. N Engl J Med2013;369:1095. CrossRef

11. KohlerBA, WardE, McCarthyBJ, et al.Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst2011;103:714. CrossRef

12. TroisiRJ, FreedmanAN, DevesaSS. Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975–1994. Cancer1999;85:1670. CrossRef

13. ThornM, BergstromR, KressnerU, et al.Trends in colorectal cancer incidence in Sweden 1959–93 by gender, localization, time period, and birth cohort. Cancer Causes Control1998;9:145. CrossRef

14. MamazzaJ, GordonPH. The changing distribution of large intestinal cancer. Dis Colon Rectum1982;25:558. CrossRef

15. SchubR, SteinheberFU. Rightward shift of colon cancer. A feature of the aging gut. J Clin Gastroenterol1986;8:630. CrossRef

16. JemalA, BrayF, CenterMM, et al.Global cancer statistics. CA Cancer J Clin2011;61:69. CrossRef

17. CuradoMPEB, ShinHR, et al.Cancer Incidence in Five Continents. Lyon: IARC IARC Scientific Publications; 2007.

18. FloodDM, WeissNS, CookLS, et al.Colorectal cancer incidence in Asian migrants to the United States and their descendants. Cancer Causes Control2000;11:403. CrossRef

19. GreenwaldP. Colon cancer overview. Cancer1992;70(5 Suppl):1206. CrossRef

20. FunkhouserE, ColeP. Declining mortality rates for cancer of the rectum in the United States: 1940–1985. Cancer1992;70:2597. CrossRef

21. FungT, HuFB, FuchsC, et al.Major dietary patterns and the risk of colorectal cancer in women. Arch Intern Med2003;163:309. CrossRef

22. DixonLB, BalderHF, VirtanenMJ, et al.Dietary patterns associated with colon and rectal cancer: results from the Dietary Patterns and Cancer (DIETSCAN) Project. Am J Clin Nutr2004;80:1003.

23. SlatteryML, BoucherKM, CaanBJ, et al.Eating patterns and risk of colon cancer. Am J Epidemiol1998;148:4. CrossRef

24. WilliamsCD, SatiaJA, AdairLS, et al.Dietary patterns, food groups, and rectal cancer risk in Whites and African‐Americans. Cancer Epidemiol Biomarkers Prev2009;18:1552. CrossRef

25. GiovannucciE. Insulin and colon cancer. Cancer Causes Control1995;6:164. CrossRef

26. BenitoE, CabezaE, MorenoV, et al.Diet and colorectal adenomas: a case‐control study in Majorca. Int J Cancer1993;55:213. CrossRef

27. BenitoE, ObradorA, StiggelboutA, et al.A population‐based case‐control study of colorectal cancer in Majorca. I. Dietary factors. Int J Cancer1990;45:69. CrossRef

28. BostickRM, PotterJD, KushiLH, et al.Sugar, meat, and fat intake, and non‐dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control1994;5:38. CrossRef

29. ChaoA, ThunMJ, ConnellCJ, et al.Meat consumption and risk of colorectal cancer. JAMA2005;293:172. CrossRef

30. CrossAJ, LeitzmannMF, GailMH, et al.A prospective study of red and processed meat intake in relation to cancer risk. PLoS Med2007;4:e325. CrossRef

31. EnglishDR, MacInnisRJ, HodgeAM, et al.Red meat, chicken, and fish consumption and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev2004;13:1509.

32. GaardM, TretliS, LokenEB. Dietary factors and risk of colon cancer: a prospective study of 50,535 young Norwegian men and women. Eur J Cancer Prev1996;5:445.

33. Gerhardsson de VerdierM, HagmanU, PetersRK, et al.Meat, cooking methods and colorectal cancer: a case‐referent study in Stockholm. Int J Cancer1991;49:520. CrossRef

34. GiovannucciE, StampferMJ, ColditzG, et al.Relationship of diet to risk of colorectal adenoma in men. J Natl Cancer Inst1992;84:91. CrossRef

35. LarssonSC, RafterJ, HolmbergL, et al.Red meat consumption and risk of cancers of the proximal colon, distal colon and rectum: the Swedish Mammography Cohort. Int J Cancer2005;113:829. CrossRef

36. LeeHP, GourleyL, DuffySW, et al.Colorectal cancer and diet in an Asian population–a case‐control study among Singapore Chinese. Int J Cancer1989;43:1007. CrossRef

37. MartinezME, JacobsET, AshbeckEL, et al.Meat intake, preparation methods, mutagens and colorectal adenoma recurrence. Carcinogenesis2007;28:2019. CrossRef

38. NeugutAI, GarbowskiGC, LeeWC, et al.Dietary risk factors for the incidence and recurrence of colorectal adenomatous polyps. A case‐control study. Ann Intern Med1993;118:91. CrossRef

39. NoratT, BinghamS, FerrariP, et al.Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst2005;97:906. CrossRef

40. ShinA, ShrubsoleMJ, NessRM, et al.Meat and meat‐mutagen intake, doneness preference and the risk of colorectal polyps: the Tennessee Colorectal Polyp Study. Int J Cancer2007;121:136. CrossRef

41. SteinmetzKA, PotterJD. Food‐group consumption and colon cancer in the Adelaide Case‐Control Study. II. Meat, poultry, seafood, dairy foods and eggs. Int J Cancer1993;53:720. CrossRef

42. StemmermannGN, NomuraAM, HeilbrunLK. Dietary fat and the risk of colorectal cancer. Cancer Res1984;44:4633.

43. YoungTB, WolfDA. Case‐control study of proximal and distal colon cancer and diet in Wisconsin. Int J Cancer1988;42:167. CrossRef

44. Probst‐HenschNM, SinhaR, LongneckerMP, et al.Meat preparation and colorectal adenomas in a large sigmoidoscopy‐based case‐control study in California (United States). Cancer Causes Control1997;8:175. CrossRef

45. SugimuraT. Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process. Mutat Res1985;150:33. CrossRef

46. SugimuraT. Overview of carcinogenic heterocyclic amines. Mutat Res1997;376:211. CrossRef

47. WakabayashiK, NagaoM, EsumiH, et al.Food‐derived mutagens and carcinogens. Cancer Res1992;52(7 Suppl):2092s.

48. SinhaR, KulldorffM, ChowWH, et al.Dietary intake of heterocyclic amines, meat‐derived mutagenic activity, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev2001;10:559.

49. SinhaR, PetersU, CrossAJ, et al.Meat, meat cooking methods and preservation, and risk for colorectal adenoma. Cancer Res2005;65:8034. CrossRef

50. ButlerLM, MillikanRC, SinhaR, et al.Modification by N‐acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study. Mutat Res2008;638:162. CrossRef

51. ChiuBC, JiBT, DaiQ, et al.Dietary factors and risk of colon cancer in Shanghai, China. Cancer Epidemiol Biomarkers Prev2003;12:201.

52. KatoI, AkhmedkhanovA, KoenigK, et al.Prospective study of diet and female colorectal cancer: the New York University Women's Health Study. Nutr Cancer1997;28:276. CrossRef

53. DanielCR, McCulloughML, PatelRC, et al.Dietary intake of omega‐6 and omega‐3 fatty acids and risk of colorectal cancer in a prospective cohort of U.S. men and women. Cancer Epidemiol Biomarkers Prev2009;18:516. CrossRef

54. ShenXJ, ZhouJD, DongJY, et al.Dietary intake of n‐3 fatty acids and colorectal cancer risk: a meta‐analysis of data from 489 000 individuals. Br J Nutr2012;108:1550. CrossRef

55. KritchevskyD. Epidemiology of fibre, resistant starch and colorectal cancer. Eur J Cancer Prev1995;4:345. CrossRef

56. Le LeuRK, BrownIL, HuY, et al.Suppression of azoxymethane‐induced colon cancer development in rats by dietary resistant starch. Cancer Biol Ther2007;6:1621. CrossRef

57. Le LeuRK, BrownIL, HuY, et al.Effect of dietary resistant starch and protein on colonic fermentation and intestinal tumourigenesis in rats. Carcinogenesis2007;28:240. CrossRef

58. TrockB, LanzaE, GreenwaldP. Dietary fiber, vegetables, and colon cancer: critical review and meta‐analyses of the epidemiologic evidence. J Natl Cancer Inst1990;82:650. CrossRef

59. HoweGR, BenitoE, CastelletoR, et al.Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case‐control studies. J Natl Cancer Inst1992;84:1887. CrossRef

60. WillettWC, StampferMJ, ColditzGA, et al.Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med1990;323:1664. CrossRef

61. GoldbohmRA, van den BrandtPA, van't VeerP, et al.A prospective cohort study on the relation between meat consumption and the risk of colon cancer. Cancer Res1994;54:718.

62. FuchsCS, GiovannucciEL, ColditzGA, et al.Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med1999;340:169. CrossRef

63. PietinenP, MalilaN, VirtanenM, et al.Diet and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes Control1999;10:387. CrossRef

64. KoushikA, HunterDJ, SpiegelmanD, et al.Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst2007;99:1471. CrossRef

65. SchatzkinA, LanzaE, CorleD, et al.Lack of effect of a low‐fat, high‐fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med2000;342:1149. CrossRef

66. AlbertsDS, MartinezME, RoeDJ, et al.Lack of effect of a high‐fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med2000;342:1156. CrossRef

67. Bonithon‐KoppC, KronborgO, GiacosaA, et al.Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet2000;356:1300. CrossRef

68. MathersJC, MovahediM, MacraeF, et al.Long‐term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol2012;13:1242. CrossRef

69. MartinezME, WillettWC. Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prev1998;7:163.

70. WuK, WillettWC, FuchsCS, et al.Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst2002;94:437. CrossRef

71. ChoE, Smith‐WarnerSA, SpiegelmanD, et al.Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst2004;96:1015. CrossRef

72. BaronJA, BeachM, MandelJS, et al.Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med1999;340:101. CrossRef

73. NewmarkHL, WargovichMJ, BruceWR. Colon cancer and dietary fat, phosphate, and calcium: a hypothesis. J Natl Cancer Inst1984;72:1323.

74. Van der MeerR, De VriesHT. Differential binding of glycine‐ and taurine‐conjugated bile acids to insoluble calcium phosphate. Biochem J1985;229:265. CrossRef

75. FedirkoV, BostickRM, FlandersWD, et al.Effects of vitamin D and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev2009;18:2933. CrossRef

76. FedirkoV, BostickRM, FlandersWD, et al.Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double‐blind, placebo‐controlled clinical trial. Cancer Prev Res (Phila)2009;2:213. CrossRef

77. GorhamED, GarlandCF, GarlandFC, et al.Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol2005;97:179. CrossRef

78. Wactawski‐WendeJ, KotchenJM, AndersonGL, et al.Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med2006;354:684. CrossRef

79. SanjoaquinMA, AllenN, CoutoE, et al.Folate intake and colorectal cancer risk: a meta‐analytical approach. Int J Cancer2005;113:825. CrossRef

80. SchernhammerES, OginoS, FuchsCS. Folate and vitamin B6 intake and risk of colon cancer in relation to p53 expression. Gastroenterology2008;135:770. CrossRef

81. StevensVL, McCulloughML, SunJ, et al.High levels of folate from supplements and fortification are not associated with increased risk of colorectal cancer. Gastroenterology2011;141:98, e1. CrossRef

82. LeeJE, WillettWC, FuchsCS, et al.Folate intake and risk of colorectal cancer and adenoma: modification by time. Am J Clin Nutr2011;93:817. CrossRef

83. WuK, PlatzEA, WillettWC, et al.A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr2009;90:1623. CrossRef

84. FigueiredoJC, MottLA, GiovannucciE, et al.Folic acid and prevention of colorectal adenomas: a combined analysis of randomized clinical trials. Int J Cancer2011;129:192. CrossRef

85. LoganRF, GraingeMJ, ShepherdVC, et al.Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology2008;134:29. CrossRef

86. ColeBF, BaronJA, SandlerRS, et al.Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA2007;297:2351. CrossRef

87. LarssonSC, GiovannucciE, WolkA. Vitamin B6 intake, alcohol consumption, and colorectal cancer: a longitudinal population‐based cohort of women. Gastroenterology2005;128:1830. CrossRef

88. Le MarchandL, WhiteKK, NomuraAM, et al.Plasma levels of B vitamins and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev2009;18:2195. CrossRef

89. LeeJE, LiH, GiovannucciE, et al.Prospective study of plasma vitamin B6 and risk of colorectal cancer in men. Cancer Epidemiol Biomarkers Prev2009;18:1197. CrossRef

90. TheodoratouE, FarringtonSM, TenesaA, et al.Dietary vitamin B6 intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev2008;17:171. CrossRef

91. WeiEK, GiovannucciE, SelhubJ, et al.Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women. J Natl Cancer Inst2005;97:684. CrossRef

92. ZhangSM, MooreSC, LinJ, et al.Folate, vitamin B6, multivitamin supplements, and colorectal cancer risk in women. Am J Epidemiol2006;163:108. CrossRef

93. RaymanMP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc2005;64:527. CrossRef

94. BjelakovicG, NikolovaD, SimonettiRG, et al.Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta‐analysis. Lancet2004;364:1219. CrossRef

95. ClarkLC, HixsonLJ, CombsGFJr, et al.Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev1993;2:41.

96. Connelly‐FrostA, PooleC, SatiaJA, et al.Selenium, apoptosis, and colorectal adenomas. Cancer Epidemiol Biomarkers Prev2006;15:486. CrossRef

97. JacobsET, JiangR, AlbertsDS, et al.Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst2004;96:1669. CrossRef

98. PetersU, ChatterjeeN, ChurchTR, et al.High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiol Biomarkers Prev2006;15:315. CrossRef

99. ClarkLC, CombsGFJr, TurnbullBW, et al.Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA1996;276:1957. CrossRef

100. ReidME, Duffield‐LillicoAJ, SungaA, et al.Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int J Cancer2006;118:1777. CrossRef

101. LippmanSM, KleinEA, GoodmanPJ, et al.Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301:39. CrossRef

102. MacLennanR, MacraeF, BainC, et al.Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst1995;87:1760. CrossRef

103. GreenbergER, BaronJA, TostesonTD, et al.A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med1994;331:141. CrossRef

104. ChoE, Smith‐WarnerSA, RitzJ, et al.Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med2004;140:603. CrossRef

105. PoynterJN, HaileRW, SiegmundKD, et al.Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev2009;18:2745. CrossRef

106. NanH, LeeJE, RimmEB, et al.Prospective study of alcohol consumption and the risk of colorectal cancer before and after folic acid fortification in the United States. Ann Epidemiol2013;23:558. CrossRef

107. ChaoA, ThunMJ, JacobsEJ, et al.Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. J Natl Cancer Inst2000;92:1888. CrossRef

108. AbramsJA, TerryMB, NeugutAI. Cigarette smoking and the colorectal adenoma‐carcinoma sequence. Gastroenterology2008;134:617. CrossRef

109. GongJ, HutterC, BaronJA, et al.A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. Cancer Epidemiol Biomarkers Prev2012;21:1974. CrossRef

110. HannanLM, JacobsEJ, ThunMJ. The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. Cancer Epidemiol Biomarkers Prev2009;18:3362. CrossRef

111. NingY, WangL, GiovannucciEL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev2010;11:19. CrossRef

112. GiovannucciE, AscherioA, RimmEB, et al.Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med1995;122:327. CrossRef

113. WolinKY, YanY, ColditzGA, et al.Physical activity and colon cancer prevention: a meta‐analysis. Br J Cancer2009;100:611. CrossRef

114. DornschneiderG, IzbickiJR, WilkerDK, et al.The effects of sex steroids on colon carcinogenesis. Anticancer Drugs1990;1:15. CrossRef

115. CampagnoliC, BigliaN, AltareF, et al.Differential effects of oral conjugated estrogens and transdermal estradiol on insulin‐like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol1993;7:251. CrossRef

116. CalleEE, Miracle‐McMahillHL, ThunMJ, et al.Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst1995;87:517. CrossRef

117. CorraoG, ZambonA, ContiV, et al.Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol2008;19:150. CrossRef

118. FernandezE, La VecchiaC, BragaC, et al.Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev1998;7:329.

119. FolsomAR, MinkPJ, SellersTA, et al.Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health1995;85:1128. CrossRef

120. FurnerSE, DavisFG, NelsonRL, et al.A case‐control study of large bowel cancer and hormone exposure in women. Cancer Res1989;49:4936.

121. JohnsonJR, LaceyJVJr, LazovichD, et al.Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev2009;18:196. CrossRef

122. GrodsteinF, NewcombPA, StampferMJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta‐analysis. Am J Med1999;106:574. CrossRef

123. LinJH, ZhangSM, RexrodeKM, et al.Association between sex hormones and colorectal cancer risk in men and women. Clin Gastroenterol Hepatol2013;11:419. CrossRef

124. RossouwJE, AndersonGL, PrenticeRL, et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA2002;288:321. CrossRef

125. ChlebowskiRT, Wactawski‐WendeJ, RitenbaughC, et al.Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med2004;350:991. CrossRef

126. RitenbaughC, StanfordJL, WuL, et al.Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev2008;17:2609. CrossRef

127. MansonJE, ChlebowskiRT, StefanickML, et al.Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials. JAMA2013;310:1353. CrossRef

128. De MaddalenaC, VodoS, PetroniA, et al.Impact of testosterone on body fat composition. J Cell Physiol2012;227:3744. CrossRef

129. AnagnostopoulouV, PediaditakisI, AlkahtaniS, et al.Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors. Endocrinology2013;154:2446. CrossRef

130. GillessenS, TempletonA, MarraG, et al.Risk of colorectal cancer in men on long‐term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst2010;102:1760. CrossRef

131. SacksFM, PfefferMA, MoyeLA, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med1996;335:1001. CrossRef

132. PedersenTR, BergK, CookTJ, et al.Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med1996;156:2085. CrossRef

133. KayeJA, JickH. Statin use and cancer risk in the General Practice Research Database. Br J Cancer2004;90:635. CrossRef

134. CooganPF, SmithJ, RosenbergL. Statin use and risk of colorectal cancer. J Natl Cancer Inst2007;99:32. CrossRef

135. SinghH, MahmudSM, TurnerD, et al.Long‐term use of statins and risk of colorectal cancer: a population‐based study. Am J Gastroenterol2009;104:3015. CrossRef

136. RennertG, PinchevM, RennertHS, et al.Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol2011;29:1146. CrossRef

137. SinghH, NugentZ, DemersA, et al.Exposure to bisphosphonates and risk of colorectal cancer: a population‐based nested case‐control study. Cancer2012;118:1236. CrossRef

138. KhaliliH, HuangES, OginoS, et al.A prospective study of bisphosphonate use and risk of colorectal cancer. J Clin Oncol2012;30:3229. CrossRef

139. HampelH, FrankelWL, MartinE, et al.Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol2008;26:5783. CrossRef

140. KastrinosF, StoffelEM, BalmanaJ, et al.Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prev2008;17:2044. CrossRef

141. HampelH, StephensJA, PukkalaE, et al.Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology2005;129:415. CrossRef

142. BolandCR. Hereditary Nonpolyposis Colorectal Cancer, 8th edn. New York: McGraw‐Hill; 2001.

143. WinAK, LindorNM, WinshipI, et al.Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst2013;105:274. CrossRef

144. WinAK, LindorNM, JenkinsMA. Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res2013;15:R27. CrossRef

145. ChungDC, RustgiAK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med2003;138:560. CrossRef

146. HampelH, FrankelWL, MartinE, et al.Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med2005;352:1851. CrossRef

147. LindorNM, BurgartLJ, LeontovichO, et al.Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol2002;20:1043. CrossRef

148. AhnenDJ, AxellL. Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer), 16.0. LaMont JT (ed). UpToDate; 2013.

149. MoreiraL, BalaguerF, LindorN, et al.Identification of Lynch syndrome among patients with colorectal cancer. JAMA2012;308:1555. CrossRef

150. LadabaumU, WangG, TerdimanJ, et al.Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost‐effectiveness analysis. Ann Intern Med2011;155:69. CrossRef

151. JarvinenHJ, AarnioM, MustonenH, et al.Controlled 15‐year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology2000;118:829. CrossRef

152. ParryS, WinAK, ParryB, et al.Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut2011;60:950. CrossRef

153. LindorNM, RabeK, PetersenGM, et al.Lower cancer incidence in Amsterdam‐I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA2005;293:1979. CrossRef

154. BusseyHJ, VealeAM, MorsonBC. Genetics of gastrointestinal polyposis. Gastroenterology1978;74:1325.

155. JoWS, ChungDC. Genetics of hereditary colorectal cancer. Semin Oncol2005;32:11.

156. LatchfordAR, NealeKF, SpigelmanAD, et al.Features of duodenal cancer in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol2009;7:659. CrossRef

157. WongRF, TutejaAK, HaslemDS, et al.Video capsule endoscopy compared with standard endoscopy for the evaluation of small‐bowel polyps in persons with familial adenomatous polyposis (with video). Gastrointest Endosc2006;64:530. CrossRef

158. BianchiLK, BurkeCA, BennettAE, et al.Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol2008;6:180. CrossRef

159. HerraizM, BarbesinoG, FaquinW, et al.Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol2007;5:367. CrossRef

160. HamiltonSR, LiuB, ParsonsRE, et al.The molecular basis of Turcot's syndrome. N Engl J Med1995;332:839. CrossRef

161. GiardielloFM, OfferhausGJ, LeeDH, et al.Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut1993;34:1394. CrossRef

162. BurtRW, LeppertMF, SlatteryML, et al.Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology2004;127:444. CrossRef

163. LynchHT, SmyrkT, McGinnT, et al.Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer1995;76:2427. CrossRef

164. JenkinsMA, CroitoruME, MongaN, et al.Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population‐based case‐family study. Cancer Epidemiol Biomarkers Prev2006;15:312. CrossRef

165. SampsonJR, DolwaniS, JonesS, et al.Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet2003;362:39. CrossRef

166. GalaM, ChungDC. Hereditary colon cancer syndromes. Semin Oncol2011;38:490. CrossRef

167. van LierMG, WagnerA, Mathus‐VliegenEM, et al.High cancer risk in Peutz‐Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol2010;105:1258, author reply 65. CrossRef

168. GiardielloFM, BrensingerJD, TersmetteAC, et al.Very high risk of cancer in familial Peutz‐Jeghers syndrome. Gastroenterology2000;119:1447. CrossRef

169. ChanAT, ChungDC. Hereditary colon cancer: colonic polyposis syndromes. In: ChungDC, HaberDA(eds). Principles of Cancer Genetics. New York: Springer; 2010: 63. CrossRef

170. GuarinosC, Sanchez‐FortunC, Rodriguez‐SolerM, et al.Serrated polyposis syndrome: molecular, pathological and clinical aspects. World J Gastroenterol2012;18:2452. CrossRef

171. PohlC, HombachA, KruisW. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology2000;47:57.

172. EadenJA, AbramsKR, MayberryJF. The risk of colorectal cancer in ulcerative colitis: a meta‐analysis. Gut2001;48:526. CrossRef

173. RutterMD, SaundersBP, WilkinsonKH, et al.Thirty‐year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology2006;130:1030. CrossRef

174. JessT, SimonsenJ, JorgensenKT, et al.Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology2012;143:375, quiz e13‐4. CrossRef

175. HerrintonLJ, LiuL, LevinTR, et al.Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology2012;143:382. CrossRef

176. LutgensMW, van OijenMG, van der HeijdenGJ, et al.Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta‐analysis of population‐based cohort studies. Inflamm Bowel Dis2013;19:789. CrossRef

177. JessT, RungoeC, Peyrin‐BirouletL. Risk of colorectal cancer in patients with ulcerative colitis: a meta‐analysis of population‐based cohort studies. Clin Gastroenterol Hepatol2012;10:639. CrossRef

178. NguyenGC, BresslerB. A tale of two cohorts: are we overestimating the risk of colorectal cancer in inflammatory bowel disease?Gastroenterology2012;143:288. CrossRef

179. BeaugerieL, SvrcekM, SeksikP, et al.Risk of colorectal high‐grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology2013;145:166. CrossRef

180. BeaugerieL, SvrcekM, SeksikP, et al.Risk of colorectal high‐grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology2013;145:166. CrossRef

181. VelayosFS, LoftusEVJr, JessT, et al.Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case‐control study. Gastroenterology2006;130:1941. CrossRef

182. MartinezME, BaronJA, LiebermanDA, et al.A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology2009;136:832. CrossRef

183. LotfiAM, SpencerRJ, IlstrupDM, et al.Colorectal polyps and the risk of subsequent carcinoma. Mayo Clin Proc1986;61:337. CrossRef

184. Lockhart‐MummeryHE, HealdRJ. Metachronous cancer of the large intestine. Dis Colon Rectum1972;15:261. CrossRef

185. National Comprehensive Cancer Network. NCCN Guidelines: Colon Cancer, Version 3., 2013. Available at: http://www.nccn.org, accessed June 2014.

186. RamseySD, YoonP, MoonesingheR, et al.Population‐based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med2006;8:571. CrossRef

187. ButterworthAS, HigginsJP, PharoahP. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta‐analysis. Eur J Cancer2006;42:216. CrossRef

188. JohnsLE, HoulstonRS. A systematic review and meta‐analysis of familial colorectal cancer risk. Am J Gastroenterol2001;96:2992. CrossRef

189. ImperialeTF, RansohoffDF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. Ann Intern Med2012;156:703. CrossRef

190. LevinB, LiebermanDA, McFarlandB, et al.Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology2008;134:1570. CrossRef

191. RexDK, JohnsonDA, AndersonJC, et al.American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol2009;104:739. CrossRef

192. RonE, GridleyG, HrubecZ, et al.Acromegaly and gastrointestinal cancer. Cancer1991;68:1673. CrossRef

193. MelmedS, ColaoA, BarkanA, et al.Guidelines for acromegaly management: an update. J Clin Endocrinol Metab2009;94:1509. CrossRef

194. FearonER, VogelsteinB. A genetic model for colorectal tumorigenesis. Cell1990;61:759. CrossRef

195. VogelsteinB, FearonER, HamiltonSR, et al.Genetic alterations during colorectal‐tumor development. N Engl J Med1988;319:525. CrossRef

196. BurmerGC, LoebLA. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci U S A1989;86:2403. CrossRef

197. SmithG, CareyFA, BeattieJ, et al.Mutations in APC, Kirsten‐ras, and p53–alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A2002;99:9433. CrossRef

198. Al‐SohailyS, BiankinA, LeongRet al. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol2012;27:1423. CrossRef

199. GoelA, ArnoldCN, NiedzwieckiD, et al.Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res2003;63:1608.

200. LengauerC, KinzlerKW, VogelsteinB. Genetic instabilities in human cancers. Nature1998;396:643. CrossRef

201. PinoMS, ChungDC. The chromosomal instability pathway in colon cancer. Gastroenterology2010;138:2059. CrossRef

202. MiyakiM, KonishiM, Kikuchi‐YanoshitaR, et al.Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res1994;54:3011.

203. CottrellS, BicknellD, KaklamanisL, et al.Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet1992;340:626. CrossRef

204. MannB, GelosM, SiedowA, et al.Target genes of beta‐catenin‐T cell‐factor/lymphoid‐enhancer‐factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A1999;96:1603. CrossRef

205. SantiniD, LoupakisF, VincenziB, et al.High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist2008;13:1270. CrossRef

206. TakayamaT, OhiM, HayashiT, et al.Analysis of K‐ras, APC, and beta‐catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology2001;121:599. CrossRef

207. PretlowTP, PretlowTG. Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer?Biochim Biophys Acta2005;1756:83.

208. LeslieA, CareyFA, PrattNR, et al.The colorectal adenoma‐carcinoma sequence. Br J Surg2002;89:845. CrossRef

209. BeroudC, SoussiT. The UMD‐p53 database: new mutations and analysis tools. Hum Mutat2003;21:176. CrossRef

210. MartinM, Simon‐AssmannP, KedingerM, et al.DCC regulates cell adhesion in human colon cancer derived HT‐29 cells and associates with ezrin. Eur J Cell Biol2006;85:769. CrossRef

211. MehlenP, RabizadehS, SnipasSJ, et al.The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature1998;395:801. CrossRef

212. WeisenbergerDJ, SiegmundKD, CampanM, et al.CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet2006;38:787. CrossRef

213. KaneMF, LodaM, GaidaGM, et al.Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair‐defective human tumor cell lines. Cancer Res1997;57:808.

214. BolandCR, GoelA. Microsatellite instability in colorectal cancer. Gastroenterology2010;138:2073. CrossRef

215. ToyotaM, AhujaN, Ohe‐ToyotaM, et al.CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A1999;96:8681. CrossRef

216. GoelA, BolandCR. Epigenetics of colorectal cancer. Gastroenterology2012;143:1442. CrossRef

217. MarkowitzS, WangJ, MyeroffL, et al.Inactivation of the type II TGF‐beta receptor in colon cancer cells with microsatellite instability. Science1995;268:1336. CrossRef

218. PascheB, KaklamaniV, HouN, et al.TGFBR1*6A and cancer: a meta‐analysis of 12 case‐control studies. J Clin Oncol2004;22:756. CrossRef

219. SalahshorSKU, PâhlmanL, GlimeliusB, et al.Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosomes Cancer1999;26:247. CrossRef

220. EberhartCE, CoffeyRJ, RadhikaA, et al.Up‐regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology1994;107:1183.

221. FukudaR, KellyB, SemenzaGL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia‐inducible factor 1. Cancer Res2003;63:2330.

222. OshimaM, MuraiN, KargmanS, et al.Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase‐2 inhibitor. Cancer Res2001;61:1733.

223. PengL, ZhouY, WangY, et al.Prognostic significance of COX‐2 immunohistochemical expression in colorectal cancer: a meta‐analysis of the literature. PLoS ONE2013;8:e58891. CrossRef

224. MinooP, MoyerMP, JassJR. Role of BRAF‐V600E in the serrated pathway of colorectal tumourigenesis. J Pathol2007;212:124. CrossRef

225. OhmJE, McGarveyKM, YuX, et al.A stem cell‐like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet2007;39:237. CrossRef

226. MichaelMZ, O'ConnorSM, van Holst PellekaanNG, et al.Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res2003;1:882.

227. TomlinsonI, WebbE, Carvajal‐CarmonaL, et al.A genome‐wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet2007;39:984. CrossRef

228. ZankeBW, GreenwoodCM, RangrejJ, et al.Genome‐wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet2007;39:989. CrossRef

229. BroderickP, Carvajal‐CarmonaL, PittmanAM, et al.A genome‐wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet2007;39:1315. CrossRef

230. TenesaA, FarringtonSM, PrendergastJG, et al.Genome‐wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet2008;40:631. CrossRef

231. JaegerE, WebbE, HowarthK, et al.Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet2008;40:26. CrossRef

232. TomlinsonIP, WebbE, Carvajal‐CarmonaL, et al.A genome‐wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet2008;40:623. CrossRef

233. HoulstonRS, WebbE, BroderickP, et al.Meta‐analysis of genome‐wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet2008;40:1426. CrossRef

234. HoulstonRS, CheadleJ, DobbinsSE, et al.Meta‐analysis of three genome‐wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet2010;42:973. CrossRef

235. TomlinsonIP, Carvajal‐CarmonaLG, DobbinsSE, et al.Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet2011;7:e1002105. CrossRef

236. PetersU, HutterCM, HsuL, et al.Meta‐analysis of new genome‐wide association studies of colorectal cancer risk. Hum Genet2012;131:217. CrossRef

237. DunlopMG, DobbinsSE, FarringtonSM, et al.Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet2012;44:770. CrossRef

238. PetersU, JiaoS, SchumacherFR, et al.Identification of genetic susceptibility loci for colorectal tumors in a genome‐wide meta‐analysis. Gastroenterology2013;144:799. CrossRef

239. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature2012;487:330. CrossRef

240. MajorMB, CampND, BerndtJD, et al.Wilms tumor suppressor WTX negatively regulates WNT/beta‐catenin signaling. Science2007;316:1043. CrossRef

241. NaglNGJr, ZweitzigDR, ThimmapayaB, et al.The c‐myc gene is a direct target of mammalian SWI/SNF‐related complexes during differentiation‐associated cell cycle arrest. Cancer Res2006;66:1289. CrossRef

242. TopolL, ChenW, SongH, et al.Sox9 inhibits Wnt signaling by promoting beta‐catenin phosphorylation in the nucleus. J Biol Chem2009;284:3323. CrossRef

243. ChanAT, OginoS, GiovannucciEL, et al.Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti‐inflammatory drugs. Gastroenterology2011;140:799, quiz e11. CrossRef

244. ErlingerTP, PlatzEA, RifaiN, et al.C‐reactive protein and the risk of incident colorectal cancer. JAMA2004;291:585. CrossRef

245. LinWW, KarinM. A cytokine‐mediated link between innate immunity, inflammation, and cancer. J Clin Invest2007;117:1175. CrossRef

246. ArthurJC, Perez‐ChanonaE, MuhlbauerM, et al.Intestinal inflammation targets cancer‐inducing activity of the microbiota. Science2012;338:120. CrossRef

247. SobhaniI, TapJ, Roudot‐ThoravalF, et al.Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE2011;6:e16393. CrossRef

248. KosticAD, GeversD, PedamalluCS, et al.Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res2012;22:292. CrossRef

249. KosticAD, ChunE, RobertsonL. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor‐immune microenvironment. Cell Host Microbe2013;14:207. CrossRef

250. GrivennikovSI, WangK, MucidaD, et al.Adenoma‐linked barrier defects and microbial products drive IL‐23/IL‐17‐mediated tumour growth. Nature2012;491:254.

251. HuB, ElinavE, HuberS, et al.Microbiota‐induced activation of epithelial IL‐6 signaling links inflammasome‐driven inflammation with transmissible cancer. Proc Natl Acad Sci U S A2013;110:9862. CrossRef

252. RubinsteinMR, WangX, LiuW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E‐cadherin/β‐catenin signaling via its FadA adhesin. Cell Host Microbe2013;14:195. CrossRef

253. BeahrsOH, SanfelippoPM. Factors in prognosis of colon and rectal cancer. Cancer1971;28:213. CrossRef

254. Terhaar sive DrosteJS, OortFA, van der HulstRW, et al.Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population‐based observational study. BMC Cancer2010;10:332. CrossRef

255. RamosM, EstevaM, CabezaE, et al.Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: a review. Eur J Cancer2007;43:2467. CrossRef

256. RamosM, EstevaM, CabezaE, et al.Lack of association between diagnostic and therapeutic delay and stage of colorectal cancer. Eur J Cancer2008;44:510. CrossRef

257. TorringML, FrydenbergM, HansenRP, et al.Time to diagnosis and mortality in colorectal cancer: a cohort study in primary care. Br J Cancer2011;104:934. CrossRef

258. MacraeFA, St JohnDJ. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology1982;82:891.

259. KhalidU, SpiroA, BaldwinC, et al.Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer2007;15:39. CrossRef

260. LuciaS, EspositoM, Rossi FanelliF, et al.Cancer cachexia: from molecular mechanisms to patient's care. Crit Rev Oncog2012;17:315. CrossRef

261. Agmon‐LevinN, Ziv‐SokolovskyN, ShullP, et al.Carcinoma of colon presenting as fever of unknown origin. Am J Med Sci2005;329:322. CrossRef

262. CappellMS. The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Med Clin North Am2005;89:1, vii. CrossRef

263. FordAC, Veldhuyzen van ZantenSJ, RodgersCC, et al.Diagnostic utility of alarm features for colorectal cancer: systematic review and meta‐analysis. Gut2008;57:1545. CrossRef

264. VerhulstJ, FerdinandeL, DemetterP, et al.Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta‐analysis. J Clin Pathol2012;65:381. CrossRef

265. LeopoldoS, LorenaB, CinziaA, et al.Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol2008;15:1429. CrossRef

266. KangH, O'ConnellJB, MaggardMA, et al.A 10‐year outcomes evaluation of mucinous and signet‐ring cell carcinoma of the colon and rectum. Dis Colon Rectum2005;48:1161. CrossRef

267. MakinoT, TsujinakaT, MishimaH, et al.Primary signet‐ring cell carcinoma of the colon and rectum: report of eight cases and review of 154 Japanese cases. Hepatogastroenterology2006;53:845.

268. StrykerSJ, WolffBG, CulpCE, et al.Natural history of untreated colonic polyps. Gastroenterology1987;93:1009.

269. HoffG, FoersterA, VatnMH, et al.Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after detection. Scand J Gastroenterol1986;21:853. CrossRef

270. MatsuiT, YaoT, IwashitaA. Natural history of early colorectal cancer. World J Surg2000;24:1022. CrossRef

271. TomikiY, KamanoT, HayashidaY, et al.Natural history of sigmoid colon cancer: report of a patient observed for 4 years. Endoscopy2001;33:280. CrossRef

272. ChangGJ, Rodriguez‐BigasMA, SkibberJM, et al.Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst2007;99:433. CrossRef

273. NiekelMC, BipatS, StokerJ. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta‐analysis of prospective studies including patients who have not previously undergone treatment. Radiology2010;257:674. CrossRef

274. EdgeS, ByrdDR, ComptonCC, et al.AJCC (American Joint Committee on Cancer) Cancer Staging Manual. New York: Springer; 2010.

275. GaoP, SongYX, WangZN, et al.Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer? Analysis of the surveilla006Ece, epidemiology, and end results (SEER) database. BMC Cancer2013;13:123. CrossRef

276. PhippsAI, BuchananDD, MakarKW, et al.KRAS‐mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer2013;108:1757. CrossRef

277. EklofV, WikbergML, EdinS, et al.The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer2013;108:2153. CrossRef

278. PhippsAI, BuchananDD, MakarKW, et al.BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev2012;21:1792. CrossRef

279. Safaee ArdekaniG, JafarnejadSM, TanL, et al.The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta‐analysis. PLoS ONE2012;7:e47054. CrossRef

280. BokemeyerC, Van CutsemE, RougierP, et al.Addition of cetuximab to chemotherapy as first‐line treatment for KRAS wild‐type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer2012;48:1466. CrossRef

281. PhippsAI, NewcombPA, Garcia‐AlbenizX, et al.Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. Gastroenterology2012;143:51. CrossRef

282. IshihamaK, YamakawaM, SembaS, et al.Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol2007;60:1205. CrossRef

283. SchepelerT, ReinertJT, OstenfeldMS, et al.Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res2008;68:6416. CrossRef

284. SchetterAJ, LeungSY, SohnJJ, et al.MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA2008;299:425.

285. ShibuyaH, IinumaH, ShimadaR, et al.Clinicopathological and prognostic value of microRNA‐21 and microRNA‐155 in colorectal cancer. Oncology2010;79:313. CrossRef

286. ToiyamaY, TakahashiM, HurK, et al.Serum miR‐21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst2013;105:849. CrossRef

287. MalesciA, LaghiL, BianchiP, et al.Reduced likelihood of metastases in patients with microsatellite‐unstable colorectal cancer. Clin Cancer Res2007;13:3831. CrossRef

288. LanzaG, GafaR, SantiniA, et al.Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol2006;24:2359. CrossRef

289. SankilaR, AaltonenLA, JarvinenHJ, et al.Better survival rates in patients with MLH1‐associated hereditary colorectal cancer. Gastroenterology1996;110:682. CrossRef

290. FlemingM, RavulaS, TatishchevSF, et al.Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol2012;3:153.

291. BetgeJ, PollheimerMJ, LindtnerRA, et al.Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer2012;118:628. CrossRef

292. PengJ, ShengW, HuangD, et al.Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect. Cancer2011;117:1415. CrossRef

293. GarrityMM, BurgartLJ, MahoneyMR, et al.Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol2004;22:1572. CrossRef

294. ShibataD, RealeMA, LavinP, et al.The DCC protein and prognosis in colorectal cancer. N Engl J Med1996;335:1727. CrossRef

295. PagesF, BergerA, CamusM, et al.Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med2005;353:2654. CrossRef

296. LeeWS, ParkS, LeeWY, et al.Clinical impact of tumor‐infiltrating lymphocytes for survival in stage II colon cancer. Cancer2010;116:5188. CrossRef

297. MlecnikB, TosoliniM, KirilovskyA, et al.Histopathologic‐based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol2011;29:610. CrossRef

298. ThirunavukarasuP, SukumarS, SathaiahM, et al.C‐stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst2011;103:689. CrossRef

299. ParkIJ, ChoiGS, LimKH, et al.Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol2009;16:3087. CrossRef

300. RibicCM, SargentDJ, MooreMJ, et al.Tumor microsatellite‐instability status as a predictor of benefit from fluorouracil‐based adjuvant chemotherapy for colon cancer. N Engl J Med2003;349:247. CrossRef

301. SinicropeFA, FosterNR, ThibodeauSN, et al.DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5‐fluorouracil‐based adjuvant therapy. J Natl Cancer Inst2011;103:863. CrossRef

302. JoverR, NguyenTP, Perez‐CarbonellL, et al.5‐Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology2011;140:1174. CrossRef

303. IacopettaB, KawakamiK, WatanabeT. Predicting clinical outcome of 5‐fluorouracil‐based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5‐fluorouracil‐responsive subgroup?Int J Clin Oncol2008;13:498. CrossRef

304. ShenL, CatalanoPJ, BensonAB3rd, et al.Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5‐fluorouracil based chemotherapy. Clin Cancer Res2007;13:6093. CrossRef

305. Van CutsemE, KohneCH, HitreE, et al.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009;360:1408. CrossRef

306. BokemeyerC, BondarenkoI, MakhsonA, et al.Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first‐line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663. CrossRef

307. KarapetisCS, Khambata‐FordS, JonkerDJ, et al.K‐ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008;359:1757. CrossRef

308. DouillardJY, SienaS, CassidyJ, et al.Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first‐line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol2010;28:4697. CrossRef

309. TolJ, KoopmanM, CatsA, et al.Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med2009;360:563. CrossRef

310. AmadoRG, WolfM, PeetersM, et al.Wild‐type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:1626. CrossRef

311. DouillardJY, OlinerKS, SienaS, et al.Panitumumab‐FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med2013;369:1023. CrossRef

312. FlahertyKT, PuzanovI, KimKB, et al.Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med2010;363:809. CrossRef

313. MoroniM, VeroneseS, BenvenutiS, et al.Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol2005;6:279. CrossRef

314. Sartore‐BianchiA, MartiniM, MolinariF, et al.PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR‐targeted monoclonal antibodies. Cancer Res2009;69:1851. CrossRef

315. PrenenH, De SchutterJ, JacobsB, et al.PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res2009;15:3184. CrossRef

316. De RoockW, ClaesB, BernasconiD, et al.Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy‐refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol2010;11:753. CrossRef

317. LiaoX, LochheadP, NishiharaR, et al.Aspirin use, tumor PIK3CA mutation, and colorectal‐cancer survival. N Engl J Med2012;367:1596. CrossRef

318. LongstrethGF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population‐based study. Am J Gastroenterol1997;92:419.

319. ColacchioTA, FordeKA, PatsosTJ, et al.Impact of modern diagnostic methods on the management of active rectal bleeding. Ten year experience. Am J Surg1982;143:607. CrossRef

320. OhyamaT, SakuraiY, ItoM, et al.Analysis of urgent colonoscopy for lower gastrointestinal tract bleeding. Digestion2000;61:189. CrossRef

321. HalliganS, WooldrageK, DadswellE, et al.Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet2013;381:1185. CrossRef

322. AtkinW, DadswellE, WooldrageK, et al.Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. Lancet2013;381:1194. CrossRef

323. von WagnerC, GhanouniA, HalliganS, et al.Patient acceptability and psychologic consequences of CT colonography compared with those of colonoscopy: results from a multicenter randomized controlled trial of symptomatic patients. Radiology2012;263:723. CrossRef

324. ZuccaE, RoggeroE, BertoniF, et al.Primary extranodal non‐Hodgkin's lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol1997;8:727. CrossRef

325. AndrewsCN, John GillM, UrbanskiSJ, et al.Changing epidemiology and risk factors for gastrointestinal non‐Hodgkin's lymphoma in a North American population: population‐based study. Am J Gastroenterol2008;103:1762. CrossRef

326. GurneyKA, CartwrightRA, GilmanEA. Descriptive epidemiology of gastrointestinal non‐Hodgkin's lymphoma in a population‐based registry. Br J Cancer1999;79:1929. CrossRef

327. LewinKJ, RanchodM, DorfmanRF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer1978;42:693. CrossRef

328. RomagueraJ, HagemeisterFB. Lymphoma of the colon. Curr Opin Gastroenterol2005;21:80.

329. BeckPL, GillMJ, SutherlandLR. HIV‐associated non‐Hodgkin's lymphoma of the gastrointestinal tract. Am J Gastroenterol1996;91:2377.

330. BewtraM. Lymphoma in inflammatory bowel disease and treatment decisions. Am J Gastroenterol2012;107:964. CrossRef

331. KoniarisLG, DrugasG, KatzmanPJ, et al.Management of gastrointestinal lymphoma. J Am Coll Surg2003;197:127. CrossRef

332. MusallamKM, HatoumHA, BaradaK, et al.Primary colorectal lymphoma. Med Oncol2010;27:249. CrossRef

333. GonzalezQH, HeslinMJ, Davila‐CervantesA, et al.Primary colonic lymphoma. Am Surg2008;74:214.

334. WongMT, EuKW. Primary colorectal lymphomas. Colorectal Dis2006;8:586. CrossRef

335. DoolabhN, AnthonyT, SimmangC, et al.Primary colonic lymphoma. J Surg Oncol2000;74:257. CrossRef

336. FanCW, ChangchienCR, WangJY, et al.Primary colorectal lymphoma. Dis Colon Rectum2000;43:1277. CrossRef

337. TimesM. Colorectal lymphoma. Clin Colon Rectal Surg2011;24:135. CrossRef

338. GollubMJ. Imaging of gastrointestinal lymphoma. Radiol Clin North Am2008;46:287, ix. CrossRef

339. GhaiS, PattisonJ, O'MalleyME, et al.Primary gastrointestinal lymphoma: spectrum of imaging findings with pathologic correlation. Radiographics2007;27:1371. CrossRef

340. YaoJC, HassanM, PhanA, et al.One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol2008;26:3063. CrossRef

341. MaggardMA, O'ConnellJB, KoCY. Updated population‐based review of carcinoid tumors. Ann Surg2004;240:117. CrossRef

342. ItoT, SasanoH, TanakaM, et al.Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol2010;45:234. CrossRef

343. SpreadC, BerkelH, JewellL, et al.Colon carcinoid tumors. A population‐based study. Dis Colon Rectum1994;37:482. CrossRef

344. BallantyneGH, SavocaPE, FlanneryJT, et al.Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry. Cancer1992;69:2400. CrossRef

345. ModlinIM, LyeKD, KiddM. A 5‐decade analysis of 13,715 carcinoid tumors. Cancer2003;97:934. CrossRef

346. CaplinM, SundinA, NillsonO, et al.ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology2012;95:88. CrossRef

347. DanzigJB, BrandtLJ, ReinusJF, et al.Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol1991;86:715.

348. WallSD, FriedmanSL, MargulisAR. Gastrointestinal Kaposi's sarcoma in AIDS: radiographic manifestations. J Clin Gastroenterol1984;6:165. CrossRef

349. BeralV, PetermanTA, BerkelmanRL, et al.Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?Lancet1990;335:123. CrossRef

350. WeprinL, ZollingerR, ClausenK, et al.Kaposi's sarcoma: endoscopic observations of gastric and colon involvement. J Clin Gastroenterol1982;4:357. CrossRef

351. NagataN, YazakiH, OkaS. Kaposi's sarcoma presenting as a bulky tumor mass of the colon. Clin Gastroenterol Hepatol2011;9:A22. CrossRef

352. TranT, DavilaJA, El‐SeragHB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol2005;100:162. CrossRef

353. HirasakiS, SuzukiS, UmemuraS, et al.Asymptomatic colonic metastases from primary squamous cell carcinoma of the lung with a positive fecal occult blood test. World J Gastroenterol2008;14:5481. CrossRef

354. ShibaharaK, EndoK, IkedaT, et al.Colon metastasis 20 years after the removal of ovarian cancer: report of a case. Surg Today2009;39:153. CrossRef

355. AbbasTO, Al‐NaimiAR, YakoobRA, et al.Prostate cancer metastases to the rectum: a case report. World J Surg Oncol2011;9:56. CrossRef

356. PaceU, ContinoG, ChiappaA, et al.Metachronous colon metastases from gastric adenocarcinoma: a case report. Case Rep Oncol2009;2:92. CrossRef

357. TessierDJ, McConnellEJ, Young‐FadokT, et al.Melanoma metastatic to the colon: case series and review of the literature with outcome analysis. Dis Colon Rectum2003;46:441. CrossRef

358. NelsonH, PetrelliN, CarlinA, et al.Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst2001;93:583. CrossRef

359. KuhryE, SchwenkWF, GaupsetR, et al.Long‐term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev2008;(2):CD003432.

360. VolkEE, GoldblumJR, PetrasRE, et al.Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology1995;109:1801. CrossRef

361. RepiciA, PellicanoR, StrangioG, et al.Endoscopic mucosal resection for early colorectal neoplasia: pathologic basis, procedures, and outcomes. Dis Colon Rectum2009;52:1502. CrossRef

362. CranleyJP, PetrasRE, CareyWD, et al.When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma?Gastroenterology1986;91:419.

363. ParsonsHM, TuttleTM, KuntzKM, et al.Association between lymph node evaluation for colon cancer and node positivity over the past 20 years. JAMA2011;306:1089. CrossRef

364. MonsonJR, WeiserMR, BuieWD, et al.Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum2013;56:535. CrossRef

365. BorschitzT, GockelI, KiesslichR, et al.Oncological outcome after local excision of rectal carcinomas. Ann Surg Oncol2008;15:3101. CrossRef

366. WentworthS, RussellGB, TunerII, et al.Long‐term results of local excision with and without chemoradiation for adenocarcinoma of the rectum. Clin Colorectal Cancer2005;4:332. CrossRef

367. MathisKL, LarsonDW, DozoisEJ, et al.Outcomes following surgery without radiotherapy for rectal cancer. Br J Surg2012;99:137. CrossRef

368. CornishJA, TilneyHS, HeriotAG, et al.A meta‐analysis of quality of life for abdominoperineal excision of rectum versus anterior resection for rectal cancer. Ann Surg Oncol2007;14:2056. CrossRef

369. PachlerJ, Wille‐JorgensenP. Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev2012;(12):CD004323.

370. FazioVW, TekkisPP, RemziF, et al.Assessment of operative risk in colorectal cancer surgery: the Cleveland Clinic Foundation colorectal cancer model. Dis Colon Rectum2004;47:2015. CrossRef

371. TekkisPP, PolonieckiJD, ThompsonMR, et al.Operative mortality in colorectal cancer: prospective national study. BMJ2003;327:1196. CrossRef

372. LujanJ, ValeroG, BiondoS, et al.Laparoscopic versus open surgery for rectal cancer: results of a prospective multicentre analysis of 4,970 patients. Surg Endosc2013;27:295. CrossRef

373. GrossoG, BiondiA, MarventanoS, et al.Major postoperative complications and survival for colon cancer elderly patients. BMC Surg2012;12 (Suppl 1):S20. CrossRef

374. MaurerCA. Urinary and sexual function after total mesorectal excision. Recent Results Cancer Res2005;165:196. CrossRef

375. BiagiJJ, RaphaelMJ, MackillopWJ, et al.Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta‐analysis. JAMA2011;305:2335. CrossRef

376. Anon. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet1995;345:939. CrossRef

377. WolmarkN, RocketteH, FisherB, et al.The benefit of leucovorin‐modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C‐03. J Clin Oncol1993;11:1879.

378. O'ConnellMJ, MailliardJA, KahnMJ, et al.Controlled trial of fluorouracil and low‐dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol1997;15:246.

379. TwelvesC, WongA, NowackiMP, et al.Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med2005;352:2696. CrossRef

380. AndreT, BoniC, NavarroM, et al.Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol2009;27:3109. CrossRef

381. YothersG, O'ConnellMJ, AllegraCJ, et al.Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C‐07 trial, including survival and subset analyses. J Clin Oncol2011;29:3768. CrossRef

382. WebberEM, LinJS, EvelynPW. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr2010;2. pii: RRN1177. CrossRef

383. GrayRG, QuirkeP, HandleyK, et al.Validation study of a quantitative multigene reverse transcriptase‐polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol2011;29:4611. CrossRef

384. GillS, LoprinziCL, SargentDJ, et al.Pooled analysis of fluorouracil‐based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?J Clin Oncol2004;22:1797. CrossRef

385. FigueredoA, CharetteML, MarounJ, et al.Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence‐based care's gastrointestinal cancer disease site group. J Clin Oncol2004;22:3395. CrossRef

386. WuX, ZhangJ, HeX, et al.Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg2012;16:646. CrossRef

387. O'ConnorES, GreenblattDY, LoConteNK, et al.Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol2011;29:3381. CrossRef

388. BensonAB3rd, SchragD, SomerfieldMR, et al.American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol2004;22:3408. CrossRef

389. SaltzLB, NiedzwieckiD, HollisD, et al.Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol2007;25:3456. CrossRef

390. YchouM, RaoulJL, DouillardJY, et al.A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high‐risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol2009;20:674. CrossRef

391. MartensonJAJr, WillettCG, SargentDJ, et al.Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol2004;22:3277. CrossRef

392. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet2001;358:1291. CrossRef

393. DouglassHOJr, MoertelCG, MayerRJ, et al.Survival after postoperative combination treatment of rectal cancer. N Engl J Med1986;315:1294. CrossRef

394. KrookJE, MoertelCG, GundersonLL, et al.Effective surgical adjuvant therapy for high‐risk rectal carcinoma. N Engl J Med1991;324:709. CrossRef

395. SauerR, LierschT, MerkelS, et al.Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO‐94 randomized phase III trial after a median follow‐up of 11 years. J Clin Oncol2012;30:1926. CrossRef

396. SmalleySR, BenedettiJK, WilliamsonSK, et al.Phase III trial of fluorouracil‐based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol2006;24:3542. CrossRef

397. O'ConnellMJ, MartensonJA, WieandHS, et al.Improving adjuvant therapy for rectal cancer by combining protracted‐infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med1994;331:502. CrossRef

398. PetersenSH, HarlingH, KirkebyLT, et al.Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev2012;(3):CD004078.

399. HofheinzRD, WenzF, PostS, et al.Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non‐inferiority, phase 3 trial. Lancet Oncol2012;13:579. CrossRef

400. RodelC, LierschT, BeckerH, et al.Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO‐04 randomised phase 3 trial. Lancet Oncol2012;13:679. CrossRef

401. SteeleGJr. Natural history studies and the evolution of regional treatment modalities for patients with isolated liver metastases from primary colon and rectum carcinoma. Cancer Control1996;3:34.

402. MorrisEJ, FormanD, ThomasJD, et al.Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg2010;97:1110. CrossRef

403. NordlingerB, SorbyeH, GlimeliusB, et al.Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet2008;371:1007. CrossRef

404. TanakaK, TakakuraH, TakedaK, et al.Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg2009;250:935. CrossRef

405. BartlettDL, ChuE. Can metastatic colorectal cancer be cured?Oncology (Williston Park)2012;26:266.

406. MitryE, FieldsAL, BleibergH, et al.Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol2008;26:4906. CrossRef

407. YchouM, HohenbergerW, ThezenasS, et al.A randomized phase III study comparing adjuvant 5‐fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol2009;20:1964. CrossRef

408. SaltzLB, CoxJV, BlankeC, et al.Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med2000;343:905. CrossRef

409. DouillardJY, CunninghamD, RothAD, et al.Irinotecan combined with fluorouracil compared with fluorouracil alone as first‐line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000;355:1041. CrossRef

410. de GramontA, FigerA, SeymourM, et al.Leucovorin and fluorouracil with or without oxaliplatin as first‐line treatment in advanced colorectal cancer. J Clin Oncol2000;18:2938.

411. Van CutsemE, KohneCH, LangI, et al.Cetuximab plus irinotecan, fluorouracil, and leucovorin as first‐line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol2011;29:2011. CrossRef

412. DahabrehIJ, TerasawaT, CastaldiPJ, et al.Systematic review: anti‐epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med2011;154:37. CrossRef

413. PetrelliF, CabidduM, BorgonovoK, et al.Risk of venous and arterial thromboembolic events associated with anti‐EGFR agents: a meta‐analysis of randomized clinical trials. Ann Oncol2012;23:1672. CrossRef

414. HurwitzH, FehrenbacherL, NovotnyW, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:2335. CrossRef

415. HochsterHS, HartLL, RamanathanRK, et al.Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first‐line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol2008;26:3523. CrossRef

416. GruenbergerB, TamandlD, SchuellerJ, et al.Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol2008;26:1830. CrossRef

417. Van CutsemE, TaberneroJ, LakomyR, et al.Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin‐based regimen. J Clin Oncol2012;30:3499. CrossRef

418. GrotheyA, Van CutsemE, SobreroA, et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo‐controlled, phase 3 trial. Lancet2013;381:303. CrossRef

419. SaltzLB, LenzHJ, KindlerHL, et al.Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan‐refractory colorectal cancer: the BOND‐2 study. J Clin Oncol2007;25:4557. CrossRef

420. AllegraCJ, YothersG, O'ConnellMJ, et al.Bevacizumab in stage II‐III colon cancer: 5‐year update of the National Surgical Adjuvant Breast and Bowel Project C‐08 trial. J Clin Oncol2013;31:359. CrossRef

421. de GramontA, Van CutsemE, SchmollHJ, et al.Bevacizumab plus oxaliplatin‐based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol2012;13:1225. CrossRef

422. AlbertsSR, SargentDJ, NairS, et al.Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA2012;307:1383. CrossRef

423. MeyerhardtJA, NiedzwieckiD, HollisD, et al.Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA2007;298:754. CrossRef

424. MeyerhardtJA, SatoK, NiedzwieckiD, et al.Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst2012;104:1702. CrossRef

425. MeyerhardtJA, GiovannucciEL, OginoS, et al.Physical activity and male colorectal cancer survival. Arch Intern Med2009;169:2102. CrossRef

426. CampbellPT, PatelAV, NewtonCC, et al.Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J Clin Oncol2013;31:876. CrossRef

427. BlanchardCM, CourneyaKS, SteinK. Cancer survivors' adherence to lifestyle behavior recommendations and associations with health‐related quality of life: results from the American Cancer Society's SCS‐II. J Clin Oncol2008;26:2198. CrossRef

428. CampbellPT, NewtonCC, DehalAN, et al.Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study‐II Nutrition Cohort. J Clin Oncol2012;30:42. CrossRef

429. MeyerhardtJA, NiedzwieckiD, HollisD, et al.Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol2008;26:4109. CrossRef

430. DignamJJ, PoliteBN, YothersG, et al.Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst2006;98:1647. CrossRef

431. ChanJA, MeyerhardtJA, ChanAT, et al.Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol2006;24:5680. CrossRef

432. SimonMS, ChlebowskiRT, Wactawski‐WendeJ, et al.Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol2012;30:3983. CrossRef

433. SchoenRE, PinskyPF, WeissfeldJL, et al.Colorectal‐cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med2012;366:2345. CrossRef

434. ZauberAG, WinawerSJ, O'BrienMJ, et al.Colonoscopic polypectomy and long‐term prevention of colorectal‐cancer deaths. N Engl J Med2012;366:687. CrossRef

435. DannenbergAJ, LippmanSM, MannJR, et al.Cyclooxygenase‐2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol2005;23:254. CrossRef

436. CastelloneMD, TeramotoH, WilliamsBO, et al.Prostaglandin E2 promotes colon cancer cell growth through a Gs‐axin‐beta‐catenin signaling axis. Science2005;310:1504. CrossRef

437. TsujiiM, KawanoS, DuBoisRN. Cyclooxygenase‐2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A1997;94:3336. CrossRef

438. RigauJ, PiqueJM, RubioE, et al.Effects of long‐term sulindac therapy on colonic polyposis. Ann Intern Med1991;115:952. CrossRef

439. YangW, VelcichA, MariadasonJ, et al.p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res2001;61:6297.

440. ThunMJ, JacobsEJ, PatronoC. The role of aspirin in cancer prevention. Nat Rev Clin Oncol2012;9:259. CrossRef

441. YamamotoY, YinMJ, LinKM, et al.Sulindac inhibits activation of the NF‐kappaB pathway. J Biol Chem1999;274:27307. CrossRef

442. SlatteryML, SamowitzW, HoffmanM, et al.Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin‐related pathway. Cancer Epidemiol Biomarkers Prev2004;13:538.

443. NishiharaR, LochheadP, KuchibaA, et al.Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA2013;309:2563. CrossRef

444. Garcia‐AlbenizX, ChanAT. Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol2011;25:461. CrossRef

445. BosettiC, RosatoV, GallusS, et al.Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol2012;23:1403. CrossRef

446. ColeBF, LoganRF, HalabiS, et al.Aspirin for the chemoprevention of colorectal adenomas: meta‐analysis of the randomized trials. J Natl Cancer Inst2009;101:256. CrossRef

447. RothwellPM, WilsonM, ElwinCE, et al.Long‐term effect of aspirin on colorectal cancer incidence and mortality: 20‐year follow‐up of five randomised trials. Lancet2010;376:1741. CrossRef

448. SturmerT, GlynnRJ, LeeIM, et al.Aspirin use and colorectal cancer: post‐trial follow‐up data from the Physicians' Health Study. Ann Intern Med1998;128:713. CrossRef

449. CookNR, LeeIM, GazianoJM, et al.Low‐dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA2005;294:47. CrossRef

450. CookNR, LeeIM, ZhangSM, et al.Alternate‐day, low‐dose aspirin and cancer risk: long‐term observational follow‐up of a randomized trial. Ann Intern Med2013;159:77. CrossRef

451. ChanAT, OginoS, FuchsCS. Aspirin and the risk of colorectal cancer in relation to the expression of COX‐2. N Engl J Med2007;356:2131. CrossRef

452. BurnJ, BishopDT, ChapmanPD, et al.A randomized placebo‐controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila)2011;4:655. CrossRef

453. BurnJ, BishopDT, MecklinJP, et al.Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med2008;359:2567. CrossRef

454. BurnJ, MathersJ, BishopDT. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results Cancer Res2013;191:157. CrossRef

455. LabayleD, FischerD, VielhP, et al.Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology1991;101:635.

456. GiardielloFM, HamiltonSR, KrushAJ, et al.Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med1993;328:1313. CrossRef

457. GiardielloFM, YangVW, HylindLM, et al.Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med2002;346:1054. CrossRef

458. MeyskensFLJr, McLarenCE, PelotD, et al.Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo‐controlled, double‐blind trial. Cancer Prev Res (Phila)2008;1:32. CrossRef

459. LaoCD, BackoffP, ShotlandLI, et al.Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev2004;13:1250.

460. ZellJA, PelotD, ChenWP, et al.Risk of cardiovascular events in a randomized placebo‐controlled, double‐blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila)2009;2:209. CrossRef

461. SteinbachG, LynchPM, PhillipsRK, et al.The effect of celecoxib, a cyclooxygenase‐2 inhibitor, in familial adenomatous polyposis. N Engl J Med2000;342:1946. CrossRef

462. HiguchiT, IwamaT, YoshinagaK, et al.A randomized, double‐blind, placebo‐controlled trial of the effects of rofecoxib, a selective cyclooxygenase‐2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res2003;9:4756.

463. BaronJA, SandlerRS, BresalierRS, et al.A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology2006;131:1674. CrossRef

464. SolomonSD, WittesJ, FinnPV, et al.Cardiovascular risk of celecoxib in 6 randomized placebo‐controlled trials: the cross trial safety analysis. Circulation2008;117:2104. CrossRef

465. ChanAT, SimaCS, ZauberAG, et al.C‐reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila)2011;4:1172. CrossRef

466. MaS, MaCC. Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor‐beta superfamily. Cytokine Growth Factor Rev2011;22:167.

467. AntonopoulosAS, MargaritisM, LeeR, et al.Statins as anti‐inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des2012;18:1519. CrossRef

468. DemierreMF, HigginsPD, GruberSB, et al.Statins and cancer prevention. Nat Rev Cancer2005;5:930. CrossRef

469. DavignonJ, JacobRF, MasonRP. The antioxidant effects of statins. Coron Artery Dis2004;15:251. CrossRef

470. MalickiS, WiniarskiM, MatlokM, et al.IL‐6 and IL‐8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. J Physiol Pharmacol2009;60:141.

471. SmaldoneC, BrugalettaS, PazzanoV, et al.Immunomodulator activity of 3‐hydroxy‐3‐methilglutaryl‐CoA inhibitors. Cardiovasc Hematol Agents Med Chem2009;7:279. CrossRef

472. ElewaHF, El‐RemessyAB, SomanathPR, et al.Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy2010;30:169. CrossRef

473. LochheadP, ChanAT. Statins and colorectal cancer. Clin Gastroenterol Hepatol2013;11:109, quiz e13. CrossRef

474. BrowningDR, MartinRM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer2007;120:833. CrossRef

475. BonovasS, FilioussiK, FlordellisCS, et al.Statins and the risk of colorectal cancer: a meta‐analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol2007;25:3462. CrossRef

476. TaylorML, WellsBJ, SmolakMJ. Statins and cancer: a meta‐analysis of case‐control studies. Eur J Cancer Prev2008;17:259. CrossRef

477. EmbersonJR, KearneyPM, BlackwellL, et al.Lack of effect of lowering LDL cholesterol on cancer: meta‐analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE2012;7:e29849. CrossRef

478. FordI, MurrayH, PackardCJ, et al.Long‐term follow‐up of the West of Scotland Coronary Prevention Study. N Engl J Med2007;357:1477. CrossRef

479. BulbuliaR, BowmanL, WallendszusK, et al.Effects on 11‐year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high‐risk individuals: a randomised controlled trial. Lancet2011;378:2013. CrossRef

480. SiddiquiA, NazarioHE, PatelM, et al.Reduction in low‐density lipoprotein cholesterol levels during statin therapy is associated with a reduced incidence of advanced colon polyps. Am J Med Sci2009;338:378. CrossRef

481. BertagnolliMM, HsuM, HawkET, et al.Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila)2010;3:588. CrossRef

482. ZhangZJ, ZhengZJ, KanH, et al.Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta‐analysis. Diabetes Care2011;34:2323. CrossRef

483. PlottelCS, BlaserMJ. Microbiome and malignancy. Cell Host Microbe2011;10:324. CrossRef

484. ChanAT, GiovannucciEL. Prevention of colorectal cancer. Gastroenterology2010;138:2029. CrossRef